Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
- CAS Registry Number
- 138661-02-6
- Molecular formula
- C63H87N13O19S2
- Molecular weight
- 1394.6 g/mol
- Drug class
- Somatostatin analogueDTPA-conjugated peptide radiopharmaceutical ligand
- Mechanism of action
- The pentetreotide peptide moiety binds somatostatin receptors, particularly subtype 2, expressed on many neuroendocrine tumour cells. When conjugated with indium-111, the radiolabel enables scintigraphic localisation of somatostatin-receptor-positive lesions.
- Indications / reported uses
- Used as the peptide component of indium In-111 pentetreotide (octreotide DTPA) for scintigraphic imaging of somatostatin-receptor-positive neuroendocrine tumours; the radiolabelled product, not unlabelled pentetreotide alone, is the diagnostic radiopharmaceutical.
Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/indium-in-111-pentetreotide · https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020314s012lbl.pdf